JP2010516684A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516684A5
JP2010516684A5 JP2009546447A JP2009546447A JP2010516684A5 JP 2010516684 A5 JP2010516684 A5 JP 2010516684A5 JP 2009546447 A JP2009546447 A JP 2009546447A JP 2009546447 A JP2009546447 A JP 2009546447A JP 2010516684 A5 JP2010516684 A5 JP 2010516684A5
Authority
JP
Japan
Prior art keywords
intranasal
insufflator
microspheres
compositions
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009546447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516684A (ja
JP5502494B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/000802 external-priority patent/WO2008091588A1/en
Publication of JP2010516684A publication Critical patent/JP2010516684A/ja
Publication of JP2010516684A5 publication Critical patent/JP2010516684A5/ja
Application granted granted Critical
Publication of JP5502494B2 publication Critical patent/JP5502494B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009546447A 2007-01-22 2008-01-22 メタニコチンアナログの鼻腔内、バッカル、または舌下投与 Expired - Fee Related JP5502494B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88601207P 2007-01-22 2007-01-22
US60/886,012 2007-01-22
US89580507P 2007-03-20 2007-03-20
US60/895,805 2007-03-20
PCT/US2008/000802 WO2008091588A1 (en) 2007-01-22 2008-01-22 Intranasal, buccal, and sublingual administration of metanicotine analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014002875A Division JP2014098000A (ja) 2007-01-22 2014-01-10 メタニコチンアナログの鼻腔内、バッカル、または舌下投与

Publications (3)

Publication Number Publication Date
JP2010516684A JP2010516684A (ja) 2010-05-20
JP2010516684A5 true JP2010516684A5 (enExample) 2011-03-03
JP5502494B2 JP5502494B2 (ja) 2014-05-28

Family

ID=39433897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009546447A Expired - Fee Related JP5502494B2 (ja) 2007-01-22 2008-01-22 メタニコチンアナログの鼻腔内、バッカル、または舌下投与
JP2014002875A Pending JP2014098000A (ja) 2007-01-22 2014-01-10 メタニコチンアナログの鼻腔内、バッカル、または舌下投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014002875A Pending JP2014098000A (ja) 2007-01-22 2014-01-10 メタニコチンアナログの鼻腔内、バッカル、または舌下投与

Country Status (4)

Country Link
US (1) US20100028447A1 (enExample)
EP (1) EP2112923A1 (enExample)
JP (2) JP5502494B2 (enExample)
WO (2) WO2008091592A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2351315C2 (ru) 2003-07-24 2009-04-10 Смитклайн Бичам Корпорейшн Пленки, растворяющиеся в полости рта
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型
CN101528698A (zh) 2006-05-09 2009-09-09 阿斯利康公司 (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式
KR20100052490A (ko) * 2007-07-31 2010-05-19 타가셉트 인코포레이티드 (2s)-(4e)-n-메틸-5-(3-(5-이소프로폭시피리딘)일)-4-펜텐-2-아민의 경피투여
JP2011522886A (ja) * 2008-06-11 2011-08-04 アストラゼネカ・アクチエボラーグ (2s)−(4e)−n−メチル−5−(3−(5−イソプロポキシピリジン)イル)−4−ペンテン−2−アミンを含む舌下組成物
WO2014020155A1 (en) * 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
CA2886270C (en) 2012-10-03 2020-04-07 Proponent Biotech Gmbh Esters of short chains fatty acids for use in the treatment of immunogenic disorders
AU2014317035B2 (en) 2013-09-05 2020-02-27 Ab2 Bio Sa IL-18 binding protein (IL-18BP) in inflammatory diseases
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
SG11201706879UA (en) 2015-03-05 2017-09-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
EP3406241A4 (en) * 2016-01-18 2019-06-26 Daicel Corporation INTRAORAL RESISTANT DISTILLANT SOLUBLE PREPARATION, METHOD FOR THE MANUFACTURE THEREOF, AND POWDER COMPOSITION USED IN THE SAID MANUFACTURING METHOD
CA3045043A1 (en) 2016-12-31 2018-07-05 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
CN115154440A (zh) 2018-06-27 2022-10-11 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US20230173021A1 (en) 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023067348A1 (en) 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
EP4486367A1 (en) 2022-03-04 2025-01-08 AB2 Bio SA Il-18 binding protein (il-18bp) in the treatment of vexas
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192946A (en) * 1978-06-29 1980-03-11 Ciba-Geigy Corporation Process for producing 3-hydroxy-5-halopyridines
SE458290B (sv) * 1981-02-19 1989-03-13 Volvo Ab Anordning foer styrning av laddtrycket i en turboladdad foerbraenningsmotor
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US4582823A (en) * 1984-08-15 1986-04-15 Warner-Lambert Company Method for treating schizophrenia and medicaments therefor
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
DK161428C (da) 1985-05-10 1991-12-16 Fertin Lab As Fast, oralt cariesmodvirkende middel
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
EP0585957A1 (en) 1986-08-06 1994-03-09 Ajinomoto Co., Inc. Recombinant B-cell differentiation factor
IT1226727B (it) * 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
ES2070994T3 (es) * 1989-04-20 1995-06-16 Zambon Spa Profarmaco de dopamina.
DK365389D0 (da) 1989-07-24 1989-07-24 Fertin Lab As Antifungalt tyggegummipraeparat
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
GB2254002B (en) 1991-01-16 1995-03-22 Controlled Therapeutics Retrievable pessary
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5212188A (en) * 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
DE4337945A1 (de) 1993-11-06 1995-05-11 Labtec Gmbh Pflaster zur Behandlung von Nagelmykosen
IT1274018B (it) * 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
DE4419824A1 (de) 1994-06-07 1995-12-14 Lohmann Therapie Syst Lts Volumen-expandierbares, als Wirkstoffträger insbesondere zur oralen Anwendung geeignete flächige Anwendungsform
GB9414966D0 (en) 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5955098A (en) 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
ATE288255T1 (de) 1996-04-12 2005-02-15 Novadel Pharma Inc Polares bukkales spray
US5869082A (en) 1996-04-12 1999-02-09 Flemington Pharmaceutical Corp. Buccal, non-polar spray for nitroglycerin
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US20020052497A1 (en) * 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
WO1997040011A1 (en) * 1996-04-23 1997-10-30 R. J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
US5814329A (en) 1996-11-12 1998-09-29 Polytherapeutics, Inc. Hydrophilic polystyrene graft copolymer vehicle for intravaginal administration of pharmacologically active agents
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US5811442A (en) * 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
US6197331B1 (en) 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
CA2306024C (en) 1997-10-01 2011-04-26 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US6068852A (en) 1997-10-11 2000-05-30 Polytherapeutics, Inc. Polymeric composition for sealing and shielding animal skin
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6576250B1 (en) 1998-03-27 2003-06-10 Cima Labs Inc. Pharmaceutical compositions for rectal and vaginal administration
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
FR2779438B1 (fr) 1998-06-03 2004-12-24 Jean Marc Aiache Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
US6232316B1 (en) * 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6365182B1 (en) 1998-08-12 2002-04-02 Cima Labs Inc. Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
EP2127642A3 (en) 1998-08-13 2010-02-24 Cima Labs, Inc. Microemulsions as solid dosage forms for oral administration
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
CA2341732C (en) 1998-08-26 2008-08-19 Teijin Limited Powder composition for nasal administration
ATE331532T1 (de) 1998-08-26 2006-07-15 Teijin Ltd Pulverförmige pernasale mittel
US6337351B1 (en) * 1998-10-22 2002-01-08 Targacept, Inc. Pharmaceutical compositions and methods for use
SE9803986D0 (sv) 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
GB9826192D0 (en) 1998-12-01 1999-01-20 Controlled Theraputics Scotlan Oral transmucosal delivery
KR100629126B1 (ko) 1999-01-14 2006-09-27 데이진 가부시키가이샤 분말체의 정량 공급장치 및 방법
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
US6369058B1 (en) 1999-02-04 2002-04-09 New Millennium Pharmaceutical Research Inc. Brain delivery of folic acid for the prevention of alzheimer's disease and stroke
AU3697200A (en) 1999-02-04 2000-08-25 New Millennium Pharmaceutical Research, Inc. Method for enhancement of delivery of thc by the administration of its prodrugs via the nasal route
BR0008650B1 (pt) 1999-03-03 2010-12-28 dispositivo de transmissão via nasal.
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
US6173851B1 (en) 1999-03-18 2001-01-16 Anesta Corporation Method and apparatus for the interim storage of medicated oral dosage forms
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
EP1187639A1 (en) 1999-06-04 2002-03-20 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
US6506769B2 (en) * 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
NZ520749A (en) 2000-02-16 2004-06-25 Bentley Pharmaceuticals Inc Pharmaceutical composition comprising a drug, a membrane-compatible permeation enhancer and a polymeric film-forming agent
US6531112B2 (en) 2000-05-15 2003-03-11 Delrx Pharmaceutical Corporation Formulations for administering calcitonin and processes for preparing the same
US6432954B1 (en) 2000-07-14 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6743812B1 (en) * 2000-07-14 2004-06-01 Targacept, Inc. Pharmaceutical compositions and methods for use
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
ATA13842001A (de) 2001-08-31 2002-10-15 Mucobiomer Biotechnologische F Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung
EP1450885B1 (en) 2001-09-28 2015-04-22 Kurve Technology, Inc. Nasal nebulizer
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
HUP0501017A3 (en) * 2001-12-14 2010-06-28 Targacept Methods and compositions for treatment of central nervous system disorders
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US20040044023A1 (en) * 2002-08-30 2004-03-04 Marc Cantillon Compositions and methods for treating or preventing memory impairment
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2006015299A2 (en) * 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
CA2580329C (en) * 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
CA2583101A1 (en) 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
US7459469B2 (en) * 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型
CL2007002684A1 (es) * 2006-09-15 2008-06-27 Astrazeneca Ab Targacept Inc Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.

Similar Documents

Publication Publication Date Title
JP2010516684A5 (enExample)
JP5252926B2 (ja) 薬物含有ワックスマトリックス粒子の製造方法、該方法に使用されるエクストルーダー、及びシロスタゾールを含有する徐放性製剤
US20240415812A1 (en) Psychoactive alkaloid extraction and composition with inhibited dephosphorylation
HRP20020182A2 (en) Benzamide formulation with histone deacetylase inhibitor activity
RS62676B1 (sr) Formulacije enzalutamida
EP2661254B1 (en) Spray drying vancomycin
US20130172271A1 (en) Pharmaceutical Spray Drying
RS59626B1 (sr) Farmaceutska kompozicija koja sadrži mirabegron
CN102920654A (zh) 缬沙坦喷雾干燥纳米混悬剂及其制备方法
JP2022082823A (ja) 医薬品
KR20210060478A (ko) 시클로세린 화합물의 제형 및 이의 응용
EP2827843B1 (en) Method for producing enteric alginate microcapsules via ionic gelation containing diclofenac or one of the salts thereof and multiparticled pharmaceutical composition containing them
KR101730865B1 (ko) 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
CN103536540A (zh) 利福平冻干粉针及其制备方法
JP2007211005A (ja) 固形製剤用組成物および固形製剤
JP2007169226A (ja) 固体分散体
CN102743384B (zh) 一种含有西他沙星的药物组合物
CN111954518B (zh) 包含甲状腺激素的用于吸入的医药干燥粉末组合物
CN102327221B (zh) 一种头孢羟氨苄脂质体固体制剂
CN111297809A (zh) 一种阿扎胞苷冻干粉针剂及其制备方法
CN102397249B (zh) 一种盐酸头孢他美酯脂质体固体制剂
CN103181924A (zh) 一种洛氟普啶药物组合物的制备方法
HK40017135A (en) Pharmaceutical preparation
CN104434850A (zh) 一种含有阿德福韦酯的口服固体药物组合物
AU2017279809A1 (en) Drug delivery device for pharmaceutical compositions